Abstract
Long-term anticoagulant treatment is highly effective in preventing recurrent Venous Thrombo-Embolism (VTE) in patients with idiopathic Deep Vein Thrombosis (DVT) of the lower limbs, though associated with an increased risk for major bleeding that may offset the benefits of anticoagulation. Accordingly to recent guidelines, patients with idiopathic DVT should be treated for at least 3 months and then should be evaluated for the risk-benefit ratio of long-term therapy. However, such ‘time for decision’ is often unclear and the optimal duration of VKA remains debatable. In recent studies, markers for the assessment of the individual risk for recurrent thrombosis have been proposed, which can be of help to establish the optimal duration of VKA treatment; among them, the D-dimer (D-d) assay and the Residual Vein Thrombosis (RVT) assessment by Compression Ultra-Sonography (CUS) were shown to be the most suitable. Studies results showed that negative results of these parameters after 3 to 6 months of therapy, identify a group of patients at low-risk for recurrent thrombosis in whom VKA treatment can be withheld. In the present review we will discuss advantages and potential limits of using these individual markers for the management of patients with a first episode of DVT of the lower limbs.
Keywords: DVT, residual vein thrombosis, D-Dimer, anticoagulation, Idiopathic Deep Vein Thrombosis, Venous Thrombo-Embolism, thrombosis, D-dimer (D-d) assay, Compression Ultra-Sonography, low-molecular weight-heparin, oral vitamin K an-tagonists, surgery, trauma, immobilization, cancer, paralysis, chronic diseases, warfarin therapy, pulmonary embolism, anticoagulant therapy, F2 G20210A (Prothrombin G20210A), F5 R506Q, Factor V Leiden, R506Q, thrombophilia, lupus anticoagulant, recent studies, antithrombotic treatment, recurrent venous thromboembolism, oral anticoagulation, low-intensity warfarin, Heterozygous Factor V Leiden, Prothrombin G20210A
Current Pharmaceutical Design
Title: Residual Vein Thrombosis and D-Dimer for Optimizing Duration of Anticoagulation in Idiopathic Deep Vein Thrombosis
Volume: 16 Issue: 31
Author(s): Alessandra Malato, Giorgia Saccullo, Alfonso Iorio, Walter Ageno and Sergio Siragusa
Affiliation:
Keywords: DVT, residual vein thrombosis, D-Dimer, anticoagulation, Idiopathic Deep Vein Thrombosis, Venous Thrombo-Embolism, thrombosis, D-dimer (D-d) assay, Compression Ultra-Sonography, low-molecular weight-heparin, oral vitamin K an-tagonists, surgery, trauma, immobilization, cancer, paralysis, chronic diseases, warfarin therapy, pulmonary embolism, anticoagulant therapy, F2 G20210A (Prothrombin G20210A), F5 R506Q, Factor V Leiden, R506Q, thrombophilia, lupus anticoagulant, recent studies, antithrombotic treatment, recurrent venous thromboembolism, oral anticoagulation, low-intensity warfarin, Heterozygous Factor V Leiden, Prothrombin G20210A
Abstract: Long-term anticoagulant treatment is highly effective in preventing recurrent Venous Thrombo-Embolism (VTE) in patients with idiopathic Deep Vein Thrombosis (DVT) of the lower limbs, though associated with an increased risk for major bleeding that may offset the benefits of anticoagulation. Accordingly to recent guidelines, patients with idiopathic DVT should be treated for at least 3 months and then should be evaluated for the risk-benefit ratio of long-term therapy. However, such ‘time for decision’ is often unclear and the optimal duration of VKA remains debatable. In recent studies, markers for the assessment of the individual risk for recurrent thrombosis have been proposed, which can be of help to establish the optimal duration of VKA treatment; among them, the D-dimer (D-d) assay and the Residual Vein Thrombosis (RVT) assessment by Compression Ultra-Sonography (CUS) were shown to be the most suitable. Studies results showed that negative results of these parameters after 3 to 6 months of therapy, identify a group of patients at low-risk for recurrent thrombosis in whom VKA treatment can be withheld. In the present review we will discuss advantages and potential limits of using these individual markers for the management of patients with a first episode of DVT of the lower limbs.
Export Options
About this article
Cite this article as:
Malato Alessandra, Saccullo Giorgia, Iorio Alfonso, Ageno Walter and Siragusa Sergio, Residual Vein Thrombosis and D-Dimer for Optimizing Duration of Anticoagulation in Idiopathic Deep Vein Thrombosis, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563428
DOI https://dx.doi.org/10.2174/138161210793563428 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales
Current Topics in Medicinal Chemistry Awareness and Perception of Thromboembolism and Thromboprophylaxis among Hospitalized Patients in Jordan
Current Clinical Pharmacology Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets α2-Antiplasmin: Potential Therapeutic Roles in Fibrin Survival and Removal
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design Approaches for the Cure of Type 1 Diabetes by Cellular and Gene Therapy
Current Gene Therapy NOAC in Acute Coronary Syndrome and AF?
Cardiovascular & Hematological Disorders-Drug Targets What is the Role for Glycoprotein IIB/IIIA Inhibitor Use in the Catheterization Laboratory in the Current Era?
Current Vascular Pharmacology Antithrombotic Agents for Acute Coronary Syndromes
Cardiovascular & Hematological Agents in Medicinal Chemistry PAI-1 - A Potential Therapeutic Target in Cancer
Current Drug Targets Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management
Cardiovascular & Hematological Disorders-Drug Targets Data Science Approaches to Pharmacogenetics
Current Molecular Medicine From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Current Status of Renal Arterial Endovascular Interventions
Current Hypertension Reviews New Substrate Analogue Inhibitors of Factor Xa Containing 4-Amidinobenzylamide as P1 Residue: Part 1
Medicinal Chemistry Radioembolization of Hepatocellular Carcinoma
Current Drug Discovery Technologies New Anti-Thrombotic Drugs for Stroke Prevention
Current Vascular Pharmacology Recent Advances in Optimal Adjunctive Antithrombotic Therapy in STEMI Patients Undergoing Primary Angioplasty: An Overview
Current Vascular Pharmacology Inhalation Gases or Gaseous Mediators As Neuroprotectants for Cerebral Ischaemia
Current Drug Targets Pericytes Within A Pulmonary Neurovascular Unit in Coronavirus Disease 2019 Elicited Pathological Changes
Current Neurovascular Research